We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer Inc. (PFE - Free Report) is one of the most well-known names in the pharmaceutical sector not just for its medicines and vaccines but also for its consumer healthcare products. This New York-based company is well known for products like Prevnar, Lyrica, Lipitor and Celebrex among others.
However, like many of its peers, PFE is facing generic competition and pricing pressure for several products. Other than that lost alliance revenues, supply shortages in legacy Hospira products, pricing pressure and rising competition are hurting the top-line.
In this scenario, investor focus remains on late-stage pipeline candidates and their commercial potential and performance of new products apart from the usual top-and bottom-line numbers.
The pharma giant has a strong record of earnings surprises. The company’s earnings surpassed expectations in each of the last four quarters, delivering an average positive surprise of 4.97%.
Currently, PFE has a Zacks Rank #2 (Buy), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earning Beat: PFE beat first quarter earnings which came in at 77 cents while our consensus called for EPS of 74 cents. Earnings rose 12% year over year.
Revenues Miss: Revenues, however, missed expectations. Pfizer posted revenues of $12.91 billion, which missed the Zacks Consensus Estimate of $13.09 billion. Revenues rose 1% from the year-ago quarter on a reported basis. However, on an operational basis, excluding the impact of currency, revenues declined 2% year over year.
2018 Guidance: Pfizer re-affirmed its previously issued guidance for 2018.
Revenues are expected in the range of $53.5 billion to $55.5 billion. The Zacks Consensus Estimate is pegged at $54.59 billion.
Adjusted earnings per share are expected in the range of $2.90 - $3.00 The Zacks Consensus Estimate is pegged at $2.96 per share.
Pre-Market Trading: Shares were down 0.6% in pre-market trading.
Check back later for our full write up on this PFE earnings report later!
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
Pfizer (PFE) Q1 Earnings Beat, Sales Miss, 2018 View Intact
Pfizer Inc. (PFE - Free Report) is one of the most well-known names in the pharmaceutical sector not just for its medicines and vaccines but also for its consumer healthcare products. This New York-based company is well known for products like Prevnar, Lyrica, Lipitor and Celebrex among others.
However, like many of its peers, PFE is facing generic competition and pricing pressure for several products. Other than that lost alliance revenues, supply shortages in legacy Hospira products, pricing pressure and rising competition are hurting the top-line.
In this scenario, investor focus remains on late-stage pipeline candidates and their commercial potential and performance of new products apart from the usual top-and bottom-line numbers.
The pharma giant has a strong record of earnings surprises. The company’s earnings surpassed expectations in each of the last four quarters, delivering an average positive surprise of 4.97%.
Currently, PFE has a Zacks Rank #2 (Buy), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earning Beat: PFE beat first quarter earnings which came in at 77 cents while our consensus called for EPS of 74 cents. Earnings rose 12% year over year.
Revenues Miss: Revenues, however, missed expectations. Pfizer posted revenues of $12.91 billion, which missed the Zacks Consensus Estimate of $13.09 billion. Revenues rose 1% from the year-ago quarter on a reported basis. However, on an operational basis, excluding the impact of currency, revenues declined 2% year over year.
2018 Guidance: Pfizer re-affirmed its previously issued guidance for 2018.
Revenues are expected in the range of $53.5 billion to $55.5 billion. The Zacks Consensus Estimate is pegged at $54.59 billion.
Adjusted earnings per share are expected in the range of $2.90 - $3.00 The Zacks Consensus Estimate is pegged at $2.96 per share.
Pre-Market Trading: Shares were down 0.6% in pre-market trading.
Check back later for our full write up on this PFE earnings report later!
Pfizer Inc. Price and Consensus
Pfizer Inc. Price and Consensus | Pfizer Inc. Quote
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>